Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.68 |
| ▸ | SRC | P12931 | 7/20 | 0.68 |
| ▸ | LYN | P07948 | 5/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | WEE1 | P30291 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | STK4 | Q13043 | 1/20 | 0.41 |
| ▸ | STK3 | Q13188 | 1/20 | 0.41 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.41 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.41 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23885005 | 0.87 | SRC (0.54) | BTKSRCLYNRIPK2ACVR1 | |
| SCHEMBL17119693 | 0.86 | BTK (0.53) | BTKSRCLYNWEE1FGFR1 | |
| SCHEMBL17119687 | 0.86 | BTK (0.67) | BTKSRCLYNWEE1FGFR1 | |
| SCHEMBL17119667 | 0.85 | SRC (0.66) | BTKSRCLYNWEE1FGFR1 | |
| SCHEMBL17119605 | 0.81 | BTK (1.00) | BTKSRCLYN | |
| SCHEMBL16964088 | 0.81 | SRC (0.58) | BTKSRCLYNWEE1FGFR1 | |
| SCHEMBL16964066 | 0.81 | BTK (0.63) | BTKSRCLYNWEE1FGFR1 | |
| SCHEMBL17120946 | 0.79 | BTK (0.48) | BTKSRCLYNWEE1FGFR1 | |
| SCHEMBL17119683 | 0.79 | SRC (0.57) | BTKSRCLYNFGFR1 | |
| SCHEMBL17119686 | 0.77 | SRC (0.51) | BTKSRCLYNFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714247-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714247-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170107215-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107215-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-9493454-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493454-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MANNKIND CORPORATION | 2015-09-24 | — | — | US | disclosed |
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MANNKIND CORPORATION | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MAP3K6, MAP3K2, MAP3K1 | BTK 245/4885SRC 161/4885LYN 330/4885 |
| US-20170107215-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MAP3K6, MAP3K2, MAP3K1 | BTK 245/4885SRC 161/4885LYN 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.